Literature DB >> 3259005

The aminoterminal-type-III procollagen peptide and proteoglycans in serum and synovial fluid of patients with rheumatoid arthritis or reactive arthritis.

K Hørslev-Petersen1, T Saxne, D Haar, B S Thomsen, K D Bentsen, P Junker, I Lorenzen.   

Abstract

The concentrations of aminoterminal-type-III procollagen (procollagen N-) peptide, and of proteoglycans were measured in knee-joint synovial fluid and serum from patients with rheumatoid arthritis or reactive arthritis. All synovial fluids contained large amounts of intact propeptide. The synovial fluid: serum propeptide ratios were high, suggesting local propeptide liberation. A correlation was demonstrated between the propeptide concentration in synovial fluid and in serum. In rheumatoid arthritis, the propeptide concentration in synovial fluid was related to local inflammatory activity, and the serum concentration was correlated with the presence of nonspecific markers of inflammation. The presence of smaller propeptide fragments in synovial fluid indicated that some degradation occurred locally. The local metabolic changes were most prominent in patients with joint erosions. Patients with nonerosive rheumatoid arthritis and reactive arthritis had similar synovial fluid propeptide concentrations. The proteoglycan content of synovial fluid was inversely related to the degree of joint destruction, and was highest in patients with reactive arthritis. No correlation was observed between the concentrations of propeptide and proteoglycan in synovial fluid. Intraarticular glucocorticoid injection reduced the levels of propeptide and proteoglycan in synovial fluid.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3259005     DOI: 10.1007/bf00541343

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  28 in total

1.  1958 Revision of diagnostic criteria for rheumatoid arthritis.

Authors:  M W ROPES; G A BENNETT; S COBB; R JACOX; R A JESSAR
Journal:  Bull Rheum Dis       Date:  1958-12

2.  Serum aminoterminal type III procollagen peptide in inflammatory and degenerative rheumatic disorders.

Authors:  K Hørslev-Petersen; K D Bentsen; P Junker; F K Mathiesen; T M Hansen; I Lorenzen
Journal:  Clin Rheumatol       Date:  1988-03       Impact factor: 2.980

3.  Metalloproteinases and collagenase inhibitors in rheumatoid synovial fluid.

Authors:  T E Cawston; E Mercer; M de Silva; B L Hazleman
Journal:  Arthritis Rheum       Date:  1984-03

4.  Serum amino terminal type III procollagen peptide and serum hyaluronan in rheumatoid arthritis: relation to clinical and serological parameters of inflammation during 8 and 24 months' treatment with levamisole, penicillamine, or azathioprine.

Authors:  K Hørslev-Petersen; K D Bentsen; A Engström-Laurent; P Junker; P Halberg; I Lorenzen
Journal:  Ann Rheum Dis       Date:  1988-02       Impact factor: 19.103

5.  Serum aminoterminal type III procollagen peptide. Relation to biosynthesis of collagen type III in experimentally induced granulation tissue in rats.

Authors:  K Hørslev-Petersen; K Y Kim; L R Pedersen; K D Bentsen; N Uldbjerg; H Oxlund; C Garbarsch; E G Hahn; D Schuppan; I Lorenzen
Journal:  APMIS       Date:  1988-09       Impact factor: 3.205

6.  Difference in cartilage proteoglycan level in synovial fluid in early rheumatoid arthritis and reactive arthritis.

Authors:  T Saxne; D Heinegård; F A Wollheim; H Pettersson
Journal:  Lancet       Date:  1985-07-20       Impact factor: 79.321

7.  Reticulin and its related structural connective tissue proteins in the rheumatoid synovium.

Authors:  D L Scott; M Salmon; K W Walton
Journal:  Histopathology       Date:  1984-05       Impact factor: 5.087

8.  [Radioimmunoassay for type II amino-terminal procollagen peptide. Technical note].

Authors:  G Heynen; S Gaspar; P Gysen; G Plomteux; P Franchimont
Journal:  C R Seances Soc Biol Fil       Date:  1981

9.  Serum amino-terminal type III procollagen peptide in rheumatoid arthritis. Relationship to disease activity, treatment, and development of joint erosions.

Authors:  K Hørslev-Petersen; K D Bentsen; P Junker; I Lorenzen
Journal:  Arthritis Rheum       Date:  1986-05

10.  Therapeutic effects on cartilage metabolism in arthritis as measured by release of proteoglycan structures into the synovial fluid.

Authors:  T Saxne; D Heinegård; F A Wollheim
Journal:  Ann Rheum Dis       Date:  1986-06       Impact factor: 19.103

View more
  4 in total

1.  Differential patterns of PMN-elastase and type III procollagen peptide in knee joint effusions due to acute and chronic sports injuries.

Authors:  K A Riel; M Jochum; P Bernett; H Fritz
Journal:  Klin Wochenschr       Date:  1991-11-15

2.  Synovial fluid and serum concentrations of aminoterminal propeptide of type III procollagen in healthy volunteers and patients with joint disease.

Authors:  M Sharif; E George; P A Dieppe
Journal:  Ann Rheum Dis       Date:  1996-01       Impact factor: 19.103

3.  Serum N terminal procollagen III fragment: a predictive marker of joint destruction in rheumatoid arthritis?

Authors:  J G Tebib; P Viguier; E Noel; F Colson; Y Barbier; M Bouvier
Journal:  Clin Rheumatol       Date:  1992-12       Impact factor: 2.980

4.  Application of markers of collagen metabolism in serum and synovial fluid for assessment of disease process in patients with rheumatoid arthritis.

Authors:  M Hakala; S Aman; R Luukkainen; L Risteli; M Kauppi; P Nieminen; J Risteli
Journal:  Ann Rheum Dis       Date:  1995-11       Impact factor: 19.103

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.